RU97105384A - APPLICATION OF 5-HT1F AGONISTS FOR INHIBITION OF 5HT1F- MEDIATED NEUROGENIC MINGIAL TRANSUSIONS - Google Patents
APPLICATION OF 5-HT1F AGONISTS FOR INHIBITION OF 5HT1F- MEDIATED NEUROGENIC MINGIAL TRANSUSIONSInfo
- Publication number
- RU97105384A RU97105384A RU97105384/14A RU97105384A RU97105384A RU 97105384 A RU97105384 A RU 97105384A RU 97105384/14 A RU97105384/14 A RU 97105384/14A RU 97105384 A RU97105384 A RU 97105384A RU 97105384 A RU97105384 A RU 97105384A
- Authority
- RU
- Russia
- Prior art keywords
- agonist
- transusions
- mingial
- 5ht1f
- inhibition
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title claims 10
- 230000002401 inhibitory effect Effects 0.000 title claims 2
- 230000001272 neurogenic Effects 0.000 title claims 2
- 102100006202 HTR1F Human genes 0.000 title 1
- 101710045381 HTR1F Proteins 0.000 title 1
- 230000001404 mediated Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000003639 vasoconstrictive Effects 0.000 claims 2
- 206010015866 Extravasation Diseases 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 230000036251 extravasation Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Claims (7)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/318,330 US5698571A (en) | 1994-10-05 | 1994-10-05 | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
US08/318,330 | 1994-10-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU97105384A true RU97105384A (en) | 1999-05-20 |
RU2183457C2 RU2183457C2 (en) | 2002-06-20 |
Family
ID=23237717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU97105384/14A RU2183457C2 (en) | 1994-10-05 | 1995-10-03 | Method for applying 5_ht5-ht1f-antagonist for inhibiting 5_ht5-ht1f-mediated neurogenic meningeal transudation |
Country Status (14)
Country | Link |
---|---|
US (1) | US5698571A (en) |
EP (1) | EP0705600A1 (en) |
JP (1) | JPH08208516A (en) |
AU (1) | AU688168B2 (en) |
CA (1) | CA2159767A1 (en) |
CZ (1) | CZ93097A3 (en) |
HU (1) | HUT77885A (en) |
NO (1) | NO971487D0 (en) |
NZ (1) | NZ296252A (en) |
RU (1) | RU2183457C2 (en) |
TW (1) | TW492864B (en) |
UA (1) | UA44284C2 (en) |
WO (1) | WO1996011006A1 (en) |
ZA (1) | ZA958314B (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6406859B1 (en) | 1992-01-08 | 2002-06-18 | Synaptic Pharmaceutical Corporation | DNA encoding a 5-HT 1F receptor and uses thereof |
DE69610793T2 (en) * | 1995-06-23 | 2001-05-03 | Lilly Co Eli | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-1OH-cyclohepta (7,6-B) indoles |
US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
US5962473A (en) * | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
AU741324B2 (en) * | 1996-08-28 | 2001-11-29 | Eli Lilly And Company | Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta(b)benzofurans |
AU4074897A (en) * | 1996-09-18 | 1998-04-14 | Eli Lilly And Company | A method for the prevention of migraine |
GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
US6066092A (en) * | 1997-11-06 | 2000-05-23 | Cady; Roger K. | Preemptive prophylaxis of migraine device and method |
HUP0102886A3 (en) * | 1998-07-27 | 2002-12-28 | Lilly Co Eli | Treatment of anxiety disorders |
GB9816556D0 (en) * | 1998-07-30 | 1998-09-30 | Pfizer Ltd | Therapy |
US6255334B1 (en) * | 1998-10-30 | 2001-07-03 | Pfizer Inc | 5HT 1 receptor agonists and metoclopramide for the treatment of migraine |
CA2327000C (en) * | 2000-11-27 | 2006-05-09 | Terry Cassaday | Chair or bed member having data storage |
ES2312585T3 (en) * | 2001-06-05 | 2009-03-01 | Ronald Aung-Din | THERAPY AGAINST MIGRAINE VIA VIA TOPICA. |
US8329734B2 (en) | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
JP5082033B2 (en) | 2001-12-21 | 2012-11-28 | エグゼリクシス パテント カンパニー エルエルシー | LXR modulator |
TWI263497B (en) | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
US7332183B2 (en) * | 2002-12-26 | 2008-02-19 | Pozen Inc. | Multilayer dosage forms containing NSAIDs and triptans |
EP1644004A4 (en) * | 2003-06-20 | 2010-10-06 | Ronald Aung-Din | Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
WO2005123043A2 (en) * | 2004-06-10 | 2005-12-29 | Duramed Pharmaceuticals, Inc. | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
CA2585857A1 (en) | 2004-11-26 | 2006-06-01 | Janssen Pharmaceutica N.V. | Isoxazoline-indole derivatives with an improved antipsychotic and anxiolytic activity |
WO2010005507A1 (en) | 2008-06-30 | 2010-01-14 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
AU2010232497B2 (en) * | 2009-04-02 | 2016-05-19 | Colucid Pharmaceuticals, Inc. | Composition of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide |
WO2011123654A1 (en) | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists |
BR112017018944A2 (en) | 2015-03-02 | 2018-05-15 | Afgin Pharma Llc | method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s) |
US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
TWI826514B (en) * | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | Chronic nightly dosing of lasmiditan for migraine prevention |
AR119319A1 (en) | 2019-07-09 | 2021-12-09 | Lilly Co Eli | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-IL]-BENZAMIDE HEMISUCCINATE AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-IL]-BENZAMIDE |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5360735A (en) * | 1992-01-08 | 1994-11-01 | Synaptic Pharmaceutical Corporation | DNA encoding a human 5-HT1F receptor, vectors, and host cells |
-
1994
- 1994-10-05 US US08/318,330 patent/US5698571A/en not_active Expired - Fee Related
-
1995
- 1995-03-10 UA UA97041603A patent/UA44284C2/en unknown
- 1995-10-03 HU HU9702287A patent/HUT77885A/en unknown
- 1995-10-03 CZ CZ97930A patent/CZ93097A3/en unknown
- 1995-10-03 AU AU39996/95A patent/AU688168B2/en not_active Ceased
- 1995-10-03 CA CA002159767A patent/CA2159767A1/en not_active Abandoned
- 1995-10-03 ZA ZA958314A patent/ZA958314B/en unknown
- 1995-10-03 NZ NZ296252A patent/NZ296252A/en unknown
- 1995-10-03 TW TW084110318A patent/TW492864B/en active
- 1995-10-03 EP EP95306998A patent/EP0705600A1/en not_active Withdrawn
- 1995-10-03 WO PCT/US1995/013010 patent/WO1996011006A1/en not_active Application Discontinuation
- 1995-10-03 JP JP7256141A patent/JPH08208516A/en active Pending
- 1995-10-03 RU RU97105384/14A patent/RU2183457C2/en not_active IP Right Cessation
-
1997
- 1997-04-02 NO NO971487A patent/NO971487D0/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU97105384A (en) | APPLICATION OF 5-HT1F AGONISTS FOR INHIBITION OF 5HT1F- MEDIATED NEUROGENIC MINGIAL TRANSUSIONS | |
DK1129708T3 (en) | Sertraline for the treatment of social phobia | |
HK1033907A1 (en) | Metal chelators for use in the treatment of alzheimer's disease. | |
EA200200649A1 (en) | COMBINATION OF SEROTONIN RETURN CAPTURE INHIBITOR AND ANTAGONIST, REVERSE AGONIST OR REPUBLIC AGONIST 5-NT2C RECEPTOR | |
ES2176600T3 (en) | DERIVATIVE OF PROPIOFENONE AND PROCEDURES FOR PREPARATION. | |
BRPI0311323B8 (en) | sglt2 c-aryl glycoside inhibitor compound, pharmaceutical composition and combination | |
EP0826671A4 (en) | Heterocyclic amide compounds and medicinal use of the same | |
CA2407100A1 (en) | 1-aroyl-piperidinyl benzamidines | |
BR0009563A (en) | Biphenyl ap2 inhibitors containing heterocyclic and method | |
ID18883A (en) | COMPETITOR 5-HT 1F | |
BR9809968A (en) | Application of thiazolidinedione derivatives in the treatment of pcos and gestational diabetes | |
NO990522L (en) | Use of <beta> -sheet mimetics as protease and kinase inhibitors of transcription factors | |
BR0113389A (en) | Compounds that inhibit factor xa activity | |
DK0772604T3 (en) | Trialzole compounds and their use as dopamine D3 ligands | |
KR970704438A (en) | Use of Thiazole and Thiadiazole Compounds as D Dopamine Receptor Ligands | |
PT1056454E (en) | UTILIZATION OF MACROLID COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | |
GB9716219D0 (en) | Prevention of metastases | |
IT1291709B1 (en) | ANALOGHI DI BUPRENORFINA HAVING ANALGESIC PROPERTIES. | |
BR9901058A (en) | N-cail and n-aroyl aralkyl amides. | |
RU94045271A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for terner's syndrome inhibition | |
EP1121932A4 (en) | Remedies for ocular diseases | |
ATE353886T1 (en) | COMPOUNDS AND METHODS FOR TREATING HYPERACTIVE BLADDER | |
WO2000002877A3 (en) | New pharmaceutically active compounds | |
MXPA03003310A (en) | The use of tiagabine for treatment of diabetic neuropathy and migraine. | |
KR950016736A (en) | How to suppress male infertility |